Steris Plc (STE) has been topic of interest among market analysts. Initiating their coverage, Jefferies gave a
‘Hold’ rating and a
$263 price target on Steris, noting potential challenges related to shifting healthcare policies. Amidst this, Steris remains a promising prospect for
dividend stocks with potential for strong
revenue growth. Steris continues to show a positive trajectory marked by significant
revenue growth and promising fiscal outlook. However, it faces
margin challenges and a cautious reaction surrounding healthcare sentiment. Analysts at Morgan Stanley and Citizens JMP recognized this growth and raised Steris's
price target to $280. STE's strong Q4 earnings report beat expectations with expanded margins and supported an upgrade to
'Strong Buy'. Steris also declared a
dividend of $0.57 per share following its strong fiscal 2025 results. Despite these successes, Steris announced layoffs due to restructuring. On a strategic note, Steris sold its renal care business while it acquired Key Surgical for $850 million. Recently, it settled a
litigation case regarding Ethylene Oxide, setting aside $48.15 million for EO claims settlement.
Steris Plc STE News Analytics from Wed, 24 Jun 2015 07:00:00 GMT to Sat, 31 May 2025 04:03:59 GMT -
Rating 5
- Innovation 3
- Information 8
- Rumor -3
